FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Jiang Wenbin				2. Issuer Name and Ticker or Trading Symbol <u>Cytek Biosciences, Inc.</u> [CTKB]							Relationship of Reporting Person(s) to Issuer (Check all applicable) One of the state							
(Last)		irst)	(Middle)	3.	. Date o	of Earliest	Transa	action (Mon	ith/Da	ay/Year)		_	X X	Officer (below)	give title		10% Owr Other (sp below)	1
C/O CYTEK BIOSCIENCES, INC.				0	07/22/2021						President and CEO							
46107 LANDING PARKWAY																		
				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) FREMO	NT C.	A	94538										X		ed by One F	•	Ü	
-														Form file Person	ed by More	than Or	ne Reporti	ng
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transaction ate Ionth/Day/	Execution Date,		Transaction Disposed Code (Instr.		ities Acquired (A) d Of (D) (Instr. 3, 4				ly (6. Owner Form: Di (D) or Ind (I) (Instr.	irect Indirect B	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount (A) or (D)		Pric	се	Transaction	ransaction(s) nstr. 3 and 4)		"	nsu. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	y Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		kpiration ate	Title	Amour or Number of Sha	er		(Instr. 4)	(3)		
Stock Option (Right to Buy)	\$17	07/22/2021		A		250,000		(1)	07	7/22/2031	Common Stock	250,0	000	\$0.00	250,000)	D	

Explanation of Responses:

1. The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.

Remarks:

/s/ Valerie Barnett, Attorney-in-07/26/2021 Fact for Wenbin Jiang

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.